Incidence and prognostic influence of DNMT3A mutations in acute myeloid leukemia - PubMed (original) (raw)
Clinical Trial
. 2011 Jul 20;29(21):2889-96.
doi: 10.1200/JCO.2011.35.4894. Epub 2011 Jun 13.
Frederik Damm, Andrea Lüdeking, Claudia Winschel, Katharina Wagner, Michael Morgan, Haiyang Yun, Gudrun Göhring, Brigitte Schlegelberger, Dieter Hoelzer, Michael Lübbert, Lothar Kanz, Walter Fiedler, Hartmut Kirchner, Gerhard Heil, Jürgen Krauter, Arnold Ganser, Michael Heuser
Affiliations
- PMID: 21670448
- DOI: 10.1200/JCO.2011.35.4894
Clinical Trial
Incidence and prognostic influence of DNMT3A mutations in acute myeloid leukemia
Felicitas Thol et al. J Clin Oncol. 2011.
Abstract
Purpose: To study the incidence and prognostic impact of mutations in DNA methyltransferase 3A (DNMT3A) in patients with acute myeloid leukemia.
Patients and methods: A total of 489 patients with AML were examined for mutations in DNMT3A by direct sequencing. The prognostic impact of DNMT3A mutations was evaluated in the context of other clinical prognostic markers and genetic risk factors (cytogenetic risk group; mutations in NPM1, FLT3, CEBPA, IDH1, IDH2, MLL1, NRAS, WT1, and WT1 SNPrs16754; expression levels of BAALC, ERG, EVI1, MLL5, MN1, and WT1).
Results: DNMT3A mutations were found in 87 (17.8%) of 489 patients with AML who were younger than 60 years of age. Patients with DNMT3A mutations were older, had higher WBC and platelet counts, more often had a normal karyotype and mutations in NPM1, FLT3, and IDH1 genes, and had higher MLL5 expression levels as compared with patients with wild-type DNMT3A. Mutations in DNMT3A independently predicted a shorter overall survival (OS; hazard ratio [HR], 1.59; 95% CI, 1.15 to 2.21; P = .005) by multivariate analysis, but were not associated with relapse-free survival (RFS) or complete remission (CR) rate when the entire patient cohort was considered. In cytogenetically normal (CN) AML, 27.2% harbored DNMT3A mutations that independently predicted shorter OS (HR = 2.46; 95% CI, 1.58 to 3.83; P < .001) and lower CR rate (OR, 0.42; 95% CI, 0.21 to 0.84; P = .015), but not RFS (P = .32). Within patients with CN-AML, DNMT3A mutations had an unfavorable effect on OS, RFS, and CR rate in NPM1/FLT3-ITD high-risk but not in low-risk patients.
Conclusion: DNMT3A mutations are frequent in younger patients with AML and are associated with an unfavorable prognosis.
Trial registration: ClinicalTrials.gov NCT00209833.
Comment in
- DNMT3A mutations in acute myeloid leukemia: impact on low-risk patients with CEBPA mutations.
Masuda S. Masuda S. J Clin Oncol. 2011 Dec 1;29(34):4592-3; author reply 4593-4. doi: 10.1200/JCO.2011.38.2127. Epub 2011 Oct 31. J Clin Oncol. 2011. PMID: 22042957 No abstract available.
Similar articles
- Prognostic significance of DNA methyltransferase 3A mutations in cytogenetically normal acute myeloid leukemia: a study by the Acute Leukemia French Association.
Renneville A, Boissel N, Nibourel O, Berthon C, Helevaut N, Gardin C, Cayuela JM, Hayette S, Reman O, Contentin N, Bordessoule D, Pautas C, Botton Sd, Revel Td, Terre C, Fenaux P, Thomas X, Castaigne S, Dombret H, Preudhomme C. Renneville A, et al. Leukemia. 2012 Jun;26(6):1247-54. doi: 10.1038/leu.2011.382. Epub 2012 Jan 13. Leukemia. 2012. PMID: 22289988 - Prognostic impact of DNMT3A mutations in patients with intermediate cytogenetic risk profile acute myeloid leukemia.
Marková J, Michková P, Burčková K, Březinová J, Michalová K, Dohnalová A, Maaloufová JS, Soukup P, Vítek A, Cetkovský P, Schwarz J. Marková J, et al. Eur J Haematol. 2012 Feb;88(2):128-35. doi: 10.1111/j.1600-0609.2011.01716.x. Epub 2011 Nov 17. Eur J Haematol. 2012. PMID: 21967546 - Impact of IDH1 R132 mutations and an IDH1 single nucleotide polymorphism in cytogenetically normal acute myeloid leukemia: SNP rs11554137 is an adverse prognostic factor.
Wagner K, Damm F, Göhring G, Görlich K, Heuser M, Schäfer I, Ottmann O, Lübbert M, Heit W, Kanz L, Schlimok G, Raghavachar AA, Fiedler W, Kirchner HH, Brugger W, Zucknick M, Schlegelberger B, Heil G, Ganser A, Krauter J. Wagner K, et al. J Clin Oncol. 2010 May 10;28(14):2356-64. doi: 10.1200/JCO.2009.27.6899. Epub 2010 Apr 5. J Clin Oncol. 2010. PMID: 20368538 - Prognostic significance of FLT3 internal tandem duplication, nucleophosmin 1, and CEBPA gene mutations for acute myeloid leukemia patients with normal karyotype and younger than 60 years: a systematic review and meta-analysis.
Port M, Böttcher M, Thol F, Ganser A, Schlenk R, Wasem J, Neumann A, Pouryamout L. Port M, et al. Ann Hematol. 2014 Aug;93(8):1279-86. doi: 10.1007/s00277-014-2072-6. Epub 2014 May 7. Ann Hematol. 2014. PMID: 24801015 Review. - Association between DNMT3A mutations and prognosis of adults with de novo acute myeloid leukemia: a systematic review and meta-analysis.
Tie R, Zhang T, Fu H, Wang L, Wang Y, He Y, Wang B, Zhu N, Fu S, Lai X, Shi J, Huang H. Tie R, et al. PLoS One. 2014 Jun 17;9(6):e93353. doi: 10.1371/journal.pone.0093353. eCollection 2014. PLoS One. 2014. PMID: 24936645 Free PMC article. Review.
Cited by
- Genomic characterization of AML with aberrations of chromosome 7: a multinational cohort of 519 patients.
Halik A, Tilgner M, Silva P, Estrada N, Altwasser R, Jahn E, Heuser M, Hou HA, Pratcorona M, Hills RK, Metzeler KH, Fenwarth L, Dolnik A, Terre C, Kopp K, Blau O, Szyska M, Christen F, Krönke J, Vasseur L, Löwenberg B, Esteve J, Valk PJM, Duchmann M, Chou WC, Linch DC, Döhner H, Gale RE, Döhner K, Bullinger L, Yoshida K, Damm F. Halik A, et al. J Hematol Oncol. 2024 Aug 19;17(1):70. doi: 10.1186/s13045-024-01590-1. J Hematol Oncol. 2024. PMID: 39160538 Free PMC article. - Symptomatic Heart Failure and Clonal Hematopoiesis-Related Mutations in Patients With Acute Myeloid Leukemia.
Kang Y, Lefebvre B, Pamies IM, Gill SI, Doucette AG, Denduluri S, Smith AM, McCurdy S, Luger S, Carver J, Scherrer-Crosbie M. Kang Y, et al. Am J Cardiol. 2024 Sep 1;226:9-17. doi: 10.1016/j.amjcard.2024.06.033. Epub 2024 Jul 6. Am J Cardiol. 2024. PMID: 38972534 - Emerging DNA Methylome Targets in FLT3-ITD-Positive Acute Myeloid Leukemia: Combination Therapy with Clinically Approved FLT3 Inhibitors.
Tecik M, Adan A. Tecik M, et al. Curr Treat Options Oncol. 2024 Jun;25(6):719-751. doi: 10.1007/s11864-024-01202-7. Epub 2024 May 2. Curr Treat Options Oncol. 2024. PMID: 38696033 Free PMC article. Review. - Influence on therapeutic outcome of platelet count at diagnosis in patients with de novo non-APL acute myeloid leukemia.
Zhang Y, Wu Q, Yuan B, Huang Y, Jiang L, Liu F, Yan P, Jiang Y, Ye J, Jiang X. Zhang Y, et al. BMC Cancer. 2023 Oct 24;23(1):1030. doi: 10.1186/s12885-023-11543-5. BMC Cancer. 2023. PMID: 37875840 Free PMC article. - Crosstalk between DNA methylation and hypoxia in acute myeloid leukaemia.
Humphries S, Bond DR, Germon ZP, Keely S, Enjeti AK, Dun MD, Lee HJ. Humphries S, et al. Clin Epigenetics. 2023 Sep 13;15(1):150. doi: 10.1186/s13148-023-01566-x. Clin Epigenetics. 2023. PMID: 37705055 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous